Physician profile
Preethi Yerram
NPI 1811008501
$35,061.11
in general payments reported to CMS, 2019-2025
18 companies · $8,982 in 2025
The $8,982 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $55.17 · 2022: $8,374 · 2023: $14K · 2024: $2,661 · 2025: $8,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,320 · Food and Beverage: $1,729 · Travel and Lodging: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,820.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,320.00 |
| Food and Beverage | $1,728.62 |
| Travel and Lodging | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16,337.73 | 2022-2024 | |
| Amgen INC. | $8,978.73 | 2024-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $5,273.57 | 2020-2025 | |
| Vifor Pharma, INC. | $3,272.97 | 2019-2023 | Veltassa, Korsuva |
| Baxter Healthcare | $447.07 | 2019-2024 | Renal - Pd |
| Akebia Therapeutics INC | $124.15 | 2019-2024 | Vafseo |
| Novartis Pharmaceuticals Corporation | $113.11 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $97.99 | 2024-2025 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $96.09 | 2019-2024 | Jynarque |
| Vantive US Healthcare LLC | $79.75 | 2025 | Renal - Acute, Renal - Pd |
| Horizon Therapeutics Plc | $59.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $31.77 | 2023-2025 | Lokelma, Farxiga |
| Chiesi USA, INC. | $31.19 | 2023 | Elfabrio |
| Apellis Pharmaceuticals, INC. | $28.67 | 2025 | |
| Genzyme Corporation | $24.97 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $22.94 | 2025 | Palindrome |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2024 | |
| Ardelyx, INC. | $19.65 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Yerram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.